Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line.

The bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF 187) abrogates doxorubicin cardiotoxicity in every mammalian species tested, but its effect on doxorubicin antitumor activity remains poorly understood. In order to better define the anthracycline-bisdioxopiperazine interaction, the ability of murine sarcoma S180 cells to form colonies in soft agar and their capability to proliferate in microtiter wells were assayed after exposure to drug at varying doses and schedules. Incubation of cell suspensions for 1 h with doxorubicin, 0.1 microgram/ml, with or without (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane, 80 micrograms/ml, produces additive cytotoxicity for the combination. Prolonged incubation (24 h) with the same drugs produces synergistic cytotoxic and antiproliferative effects at 1- and 2-log order reductions in dose. These studies indicate that the antineoplastic activity of the single agents doxorubicin and (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane is enhanced when the drugs are used in combination, and that this phenomenon is highly dose and schedule dependent.

[1]  T. Tsuruo,et al.  High calcium content of pleiotropic drug-resistant P388 and K562 leukemia and Chinese hamster ovary cells. , 1984, Cancer research.

[2]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[3]  M. Israel,et al.  Two mechanisms of adriamycin-DNA interaction in L1210 cells. , 1984, Biochemical pharmacology.

[4]  T. Tsuruo,et al.  Vincristine-resistant P388 leukemia cells contain a large amount of calcium. , 1983, Gan.

[5]  J. Doroshow.  Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. , 1983, Cancer research.

[6]  J. Riordan,et al.  Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. , 1983, Cancer research.

[7]  R. Ganapathi,et al.  Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. , 1983, Cancer research.

[8]  M. Israel,et al.  Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells. , 1983, Cancer research.

[9]  B. Hill,et al.  Concentration and time‐dependent inter‐relationships for antitumour drug cytotoxicities against tumour cells in vitro , 1983, International journal of cancer.

[10]  T. Tsuruo,et al.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. , 1983, Cancer research.

[11]  T. Tsuruo,et al.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.

[12]  C. Simone,et al.  Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. , 1982, Biochemistry.

[13]  R. Friedman,et al.  Nuclear catalyzed antibiotic free radical formation. , 1982, Cancer research.

[14]  L. Weisenthal,et al.  In vitro assays in preclinical antineoplastic drug screening. , 1981, Seminars in oncology.

[15]  V. Ferrans,et al.  Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). , 1981, Cancer research.

[16]  A. Di Marco,et al.  Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. , 1981, Cancer treatment reports.

[17]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[18]  M. Evans,et al.  ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response. , 1979, British Journal of Cancer.

[19]  B. Halliwell.  Superoxide‐dependent formation of hydroxyl radicals in the presence of iron chelates , 1978, FEBS letters.

[20]  K W Kohn,et al.  Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. , 1978, Biochimica et biophysica acta.

[21]  N. Bachur,et al.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals. , 1978, Cancer research.

[22]  I. Taylor,et al.  Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro. , 1977, British Journal of Cancer.

[23]  M. Baltezor,et al.  Utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane. , 1976, Journal of pharmaceutical sciences.

[24]  K. Dawson.  Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. , 1975, Biochemical pharmacology.

[25]  J. Venditti,et al.  Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). , 1975, Cancer chemotherapy reports.

[26]  J. L. Biedler,et al.  Cellular resistance to daunomycin in Chinese hamster cells in vitro. , 1971, Cancer research.

[27]  A. Handler,et al.  Differentiation of “Normal” and Neoplastic Cells Maintained in Tissue Culture by Implantation into Normal Hamsters.∗ , 1957, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[28]  V. Ferrans,et al.  Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. , 1985, Cancer research.

[29]  D. Witiak,et al.  Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. , 1982, Advances in pharmacology and chemotherapy.

[30]  V. Ferrans,et al.  Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. , 1981, Research communications in chemical pathology and pharmacology.

[31]  S. Krop,et al.  Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. , 1979, Cancer treatment reports.

[32]  Y. Hirshaut,et al.  Two dimensional view of combination chemotherapy in vitro , 1978, American journal of hematology.

[33]  Sartorelli Ac,et al.  DEVELOPMENT, MAINTENANCE AND ASSAY OF DRUG RESISTANCE. , 1964 .

[34]  A. Sartorelli,et al.  DEVELOPMENT, MAINTENANCE AND ASSAY OF DRUG RESISTANCE. , 1964, Methods in medical research.

[35]  John Leyden. Webb,et al.  Enzyme and metabolic inhibitors , 1963 .

[36]  W. J. Langford.  Statistical Methods , 1959, Nature.